Christopher Graham
@ChrisGrahamMD
Followers
49
Following
14
Media
2
Statuses
51
Assistant Professor of @UMNHOT @UMNCancer. Former BMT Fellow @MayoClinic. Thoughts are my own.
Joined August 2022
Impactful. In the age of PTCy, CMV exposure in donors impacts relapse mortality in allogeneic stem cell transplant. CMV seems to affect GVL.
This study found that cytomegalovirus(CMV)-seronegative #HCT recipients had better survival when their donor was also CMV-seronegative. Donor age and type mattered less than donor CMV status in this setting. Read the full study: https://t.co/Q8Dfe18fY5
0
0
1
Just Published in @ASTCT_Journal: Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Read more:
1
19
41
This study reports outcomes of non-myeloablative (NMA) #alloHCT for myelofibrosis in Eastern Denmark. NMA regimens showed satisfactory survival, with low one-year non-relapse mortality but high relapse risk. Read more: https://t.co/Ny2Z4K9ZSF
0
5
11
This is big win for patients and their caregivers.
0
0
1
For patients suffering with cGVHD, Axatilimab appears to offer some new hope, even in patients refractory to Ruxolitinib or Belumosudil.
Axatilimab Shakes Up cGVHD Treatment and Looks to Move to Earlier Line in Paradigm @ChrisGrahamMD @UMNCancer #oncology #MedEd #MedTwitter
https://t.co/Wk9YdFAaOX
0
0
1
Axatilimab Shakes Up cGVHD Treatment and Looks to Move to Earlier Line in Paradigm @ChrisGrahamMD @UMNCancer #oncology #MedEd #MedTwitter
https://t.co/Wk9YdFAaOX
onclive.com
Christopher Graham, MD, details how axatilimab has changed the care of cGVHD and highlights considerations with axatilimab, belumosudil, and ruxolitinib.
0
2
3
AGAVE 201 out in @NEJM. Remarkable efficacy of axatilimab (blocking CSF1R) in chronic #GvHD. I have some phenomenal response on trial. -Look for puffy eyes - Artifact elevation of AST/ALT/amylase/lipase due to inhibition of kupffer cells @Chhabra_mayo
https://t.co/Cm3VHV5Rb4
nejm.org
Colony-stimulating factor 1 receptor (CSF1R)–dependent monocytes and macrophages are key mediators of chronic graft-versus-host disease (GVHD), a major long-term complication of allogeneic hematopo...
3
26
87
Come join me at 1630 CEST or 930 CST at Goya 1 at #EHA2024 at the Stem Cell- Transplant 2 to see me discuss how mixed donor chimerism after transplant affects relapse after PTCy. @MayoTransplant @MayoHemeOnc @MayoCancerCare #bmtsm #ptcy
0
1
2
Just out: International Myeloma Working Group guidelines for bispecific antibodies myeloma. Limited time: Free copy link in the thread. @TheLancetOncol @paurotero @JKaufmanMD @szusmani @YiLinMDPhD @TomBmt133 @mvmateos @bdermanmd @MinnemaMonique et al
thelancet.com
Multiple myeloma remains an incurable disease, despite the development of numerous drug classes and combinations that have contributed to improved overall survival. Immunotherapies directed against...
5
72
185
BREAKING: FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory CLL or SLL #leusm #lymsm #oncology
https://t.co/1tsbkkG0Ju
0
15
20
Important alert to all transplanters! Every #TransplantAllogeneic Doc who sees #MDSsm patients should read this paper by @ColemanLindsley !! Please do NOT decline to transplant otherwise eligible TP53-mut higher risk #MDSsm Pts who have donors
ascopubs.org
PURPOSEAllogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) improves overall survival (OS). We evaluated the impact of MDS genetics on the benefit of...
10
57
168
The Spring 2024 FDA-@ASCO Fellows Day Workshop was a great success! We always enjoy meeting talented people at the start of their careers who represent the future of oncology! #OCEProjectSocrates #MedEd
@tmprowell @drjennifergao @suparnawedam @timilpatel @realrickpazdur
1
9
25
Happening now! #Tandem24 Poster reception. Stop by poster #284 to say hello and learn about Mayo Clinic’s outpatient program for #CARTcell and #BsAb
@Radhika_Bansl
@YiLinMDPhD
@jonaspaludo
@MayoCancerCare
#mmsm #lymsm #leuksm @ASTCT
0
2
11
Come by poster #164 at #Tandem24 poster session this evening to learn about patients with silent coronary artery disease having higher rates of NRM and worse OS after PTCy-based #GVHD prophylaxis. @ASTCT @MayoTransplant @MayoCVServices @MayoCancerCare
0
1
4
✈️ Off to San Antonio and ready to kick off #Tandem24 🤝 Join us at poster #284 on Thursday, 2/22 at 6:45 pm to learn about Mayo Clinic’s outpatient management of #CARTcell & #BsAb
@Radhika_Bansl
@YiLinMDPhD
@jonaspaludo
@MayoCancerCare
@ASTCT @CIBMTR #lymsm #mmsm #leuksm
1
5
20
First Tumor-infiltrating lymphocyte (TILs) approval, a big day in solid tumor cell therapy.
FDA granted accelerated approval to lifileucel for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor. https://t.co/mm5MVlPDEy
#OCENewsBurst
0
0
0
Understanding relapse in CD19 CAR-T in B-ALL guides us to future horizons in therapy for these high risk patient groups.
🌟Excited to share our review on ‘Determinants of Outcomes with CD19 CAR-T in B-ALL’, in European Journal of Haematology - exploring current landscape and future directions 🔎💉 🔗 https://t.co/7txpcUAPEG
@MiraKohorstMD @MayoHemeOnc @MayoCancerCare #leuksm #cartsm #medtwitter
0
0
2
For those attending the #ASH23 poster session tonight, stop by our poster #4477 discussing prognostic implication of B-cell phenotype in effusion based lymphomas. #lymsm #MedTwitter
@ChrisGrahamMD
0
1
3